Figure 1.

Next generation sequencing (NGS) analysis in bile samples: (a) Oncoprint showing mutation occurrence of six most frequently mutated genes across all patients. Patients are divided into those with localized and those with metastatic tumors. Concordant mutations are displayed in green, while mutations only detected in tissue or bile are displayed in blue or yellow, respectively. (b) Distribution of mutations within the bile samples. (c) KRAS allele frequency in bile samples. Patients with localized cholangiocarcinoma (CCA) were excluded, as no KRAS mutation was detected in the bile samples from these patients.